Barclays PLC reiterated their hold rating on shares of C.R. Bard, Inc. (NYSE:BCR) in a report published on Sunday morning. They currently have a $245.00 price objective on the stock.
Several other brokerages have also recently issued reports on BCR. Raymond James Financial, Inc. upgraded C.R. Bard from an outperform rating to a strong-buy rating and increased their price objective for the company from $250.00 to $265.00 in a research note on Thursday, January 5th. Needham & Company LLC restated a hold rating on shares of C.R. Bard in a research note on Friday. JMP Securities raised their price target on C.R. Bard to $255.00 in a research note on Friday. BMO Capital Markets restated a buy rating on shares of C.R. Bard in a research note on Friday. Finally, Morgan Stanley upgraded C.R. Bard from an equal weight rating to an overweight rating and raised their price target for the company from $240.00 to $260.00 in a research note on Tuesday, January 3rd. Nine investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. C.R. Bard currently has an average rating of Buy and a consensus target price of $240.20.
C.R. Bard (NYSE:BCR) traded up 5.24% during mid-day trading on Friday, reaching $238.44. The company’s stock had a trading volume of 1,788,310 shares. C.R. Bard has a one year low of $177.47 and a one year high of $240.59. The firm has a market cap of $17.53 billion, a PE ratio of 33.92 and a beta of 0.65. The stock’s 50 day moving average is $226.89 and its 200 day moving average is $221.89.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Thursday, January 26th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.74 by $0.03. The business had revenue of $967.10 million for the quarter, compared to analysts’ expectations of $956.12 million. C.R. Bard had a return on equity of 48.48% and a net margin of 14.31%. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period last year, the firm earned $2.43 earnings per share. On average, analysts anticipate that C.R. Bard will post $11.63 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 3rd. Shareholders of record on Monday, January 23rd will be issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend is Thursday, January 19th. C.R. Bard’s dividend payout ratio is presently 14.77%.
In other C.R. Bard news, VP John A. Deford sold 15,883 shares of C.R. Bard stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $218.03, for a total value of $3,462,970.49. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Frank Lupisella, Jr. sold 210 shares of C.R. Bard stock in a transaction that occurred on Monday, January 9th. The shares were sold at an average price of $232.00, for a total value of $48,720.00. The disclosure for this sale can be found here. Insiders sold a total of 41,747 shares of company stock worth $9,214,780 in the last ninety days. 0.97% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the stock. Whittier Trust Co. of Nevada Inc. increased its stake in C.R. Bard by 43.7% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 454 shares of the company’s stock worth $107,000 after buying an additional 138 shares during the last quarter. Advisory Services Network LLC increased its stake in C.R. Bard by 4.9% in the third quarter. Advisory Services Network LLC now owns 513 shares of the company’s stock worth $115,000 after buying an additional 24 shares during the last quarter. Mycio Wealth Partners LLC increased its stake in C.R. Bard by 36.4% in the second quarter. Mycio Wealth Partners LLC now owns 599 shares of the company’s stock worth $141,000 after buying an additional 160 shares during the last quarter. Penserra Capital Management LLC increased its stake in C.R. Bard by 100.0% in the third quarter. Penserra Capital Management LLC now owns 648 shares of the company’s stock worth $145,000 after buying an additional 324 shares during the last quarter. Finally, Clinton Group Inc. bought a new stake in C.R. Bard during the second quarter worth about $225,000. Institutional investors own 87.59% of the company’s stock.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.